Steroid Aromatase Inhibitors Versus Progestogens for nSAID-resistanced Late Stage Breast Cancer
Conditions
Carcinoma Breast Stage IV
Conditions: official terms
Breast Neoplasms
Conditions: Keywords
SAID, Progestogens, nSAID-resistanced, LSBC
Study Type
Observational
Study Phase
N/A
Study Design
Observational Model: Case Control, Time Perspective: Prospective
Overall Status
Recruiting
Summary
Steroid Aromatase Inhibitors and Non-Steroid Aromatase Inhibitors in Late Stage Breast Cancer is the recommended scheme in National Comprehensive Cancer Network (NCCN) guideline. In the past controlled clinical trials with small sample.
Detailed Description
A Randomized Study of Steroid Aromatase Inhibitors Versus Progestogens for Non-Steroid Aromatase Inhibitor-resistanced Late Stage Breast Cancer.The primary endpoints of the study is progression free survival (PFS). The secondary endpoints are overall response rate (ORR), overall survival (OS) and safety.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: N/A
Gender: Female
Criteria: Inclusion Criteria:

1. Patients must be the postmenopausal women

2. Patients must be diagnosed with advanced breast cancer by imageology,cytology or histopathology

3. Immunohistochemistry shows ER and/or PR positive

4. Patients ECOG score must be 0-2

5. Drug resistant about Non-Steroid Aromatase Inhibitors

Exclusion Criteria:

1. Not suitable for endocrine therapy

2. Have receive the standard Steroid Aromatase Inhibitors treatment

3. Severe hepatic dysfunction
Location
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin, China
Status: Recruiting
Contact: Yehui Shi, MD - +86-022-23340123 - shiyehui@tom.com
Start Date
April 2014
Completion Date
December 2015
Sponsors
Tianjin Medical University Cancer Institute and Hospital
Source
Tianjin Medical University Cancer Institute and Hospital
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page